Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation

Abstract

A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation.

1 . A method of treating an inflammation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Chemokine (C-C motif) ligand 2 (CCL2), thereby treating the inflammation. 
     
     
         2 . The method of  claim 1 , wherein the subject is a human subject. 
     
     
         3 . The method of  claim 1 , wherein said therapeutically effective amount is 0.1-0.6 μg/kg body weight. 
     
     
         4 . The method of  claim 1 , wherein said therapeutically effective amount is selected so as to avoid unwanted side-effects associated with elevated concentrations of CCL2. 
     
     
         5 . The method of  claim 1 , wherein said therapeutically effective amount is selected to inhibit cell migration or homing. 
     
     
         6 . The method of  claim 5 , wherein said cell is a CCR2 expressing cell. 
     
     
         7 . The method of  claim 6 , wherein said cell is an immune cell or a cancer cell. 
     
     
         8 . The method of  claim 1 , wherein the inflammation is associated with CCR2/CCL2 dependent cell migration or homing. 
     
     
         9 . The method of  claim 8 , wherein said cell migration or homing comprises T-cell migration or homing. 
     
     
         10 . The method of  claim 1 , wherein the inflammation is associated with allergy. 
     
     
         11 . The method of  claim 10 , wherein said allergy is asthma. 
     
     
         12 . The method of  claim 1 , wherein the inflammation is associated with an autoimmune disease. 
     
     
         13 . The method of  claim 12 , wherein said autoimmune disease is Rheumatoid Arthritis. 
     
     
         14 . The method of  claim 12 , wherein said autoimmune disease is colitis. 
     
     
         15 . The method of  claim 12 , wherein said autoimmune disease is multiple sclerosis. 
     
     
         16 . The method of  claim 1 , wherein the inflammation is associated with cancer. 
     
     
         17 . The method of  claim 1 , wherein the inflammation is associated with a medical condition selected from the group consisting of cancer, autoimmune, hypersensitivity, diabetes, infectious, transplantation associated and allergy. 
     
     
         18 . A unit dosage form comprising 1 ng-200 μg CCL2. 
     
     
         19 . The unit dosage form of  claim 18 , comprising 10-20 μg CCL2. 
     
     
         20 . A method of regulating cell migration, the method comprising contacting the cell with a medium comprising an amount of CCL2 selected to inhibit cell migration, thereby regulating cell migration. 
     
     
         21 . The method of  claim 20 , wherein the cell is a CCR2 expressing cell. 
     
     
         22 . The method of  claim 21 , wherein the cell is an immune cell or a cancer cell. 
     
     
         23 . The method of  claim 20 , wherein said medium further comprises a cell-migration promoting agent.